Cart
sales@molnova.com
Urelumab
CAS No. 934823-49-1
Urelumab( —— )
Catalog No. M36869 CAS No. 934823-49-1
Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 803 | Get Quote |
|
| 5MG | 1492 | Get Quote |
|
| 10MG | 2024 | Get Quote |
|
| 25MG | 2907 | Get Quote |
|
| 50MG | 3928 | Get Quote |
|
| 100MG | 5184 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameUrelumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionUrelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.
-
DescriptionUrelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number934823-49-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520.?
molnova catalog
related products
-
Pimonidazole
Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after the reduction of its nitro group.
-
Isoflupredone Acetat...
Isoflupredone Acetate is a corticosteroid with the activity of topical anti-inflammatory.
-
Beta-Sitosterol
β-Sitosterol has recently been shown to induce G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways.
